Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis

Table 5 Complications and adverse events in the fingolimod and control groups

Ref.	Size of fingolimod group	Events of fingolimod group	Size of control group	Events of control group	Risk ratio (95%CI)
Fever
Fu et al[15]	11	3	11	3	1 (0.16, 6.08)
Fu et al[16]	11	3	12	5	0.64 (0.12, 3.34)
Zhu et al[17]	22	5	25	5	1.15 (0.29, 4.51)
Suspected lung infection
Fu et al[15]	11	3	11	3	1 (0.16, 6.08)
Fu et al[16]	11	3	12	5	0.64 (0.12, 3.34)
Zhu et al[17]	22	3	25	3	1.17 (0.21, 6.39)
Adverse events occurring at least once
Fu et al[15]	11	3	11	3	1 (0.16, 6.08)
Fu et al[16]	11	4	12	6	0.72 (0.12, 4.38)
Zhu et al[17]	22	6	25	8	0.84 (0.25, 2.81)
Tian et al[18]	23	3	23	4	0.76 (0.15, 3.81)
Other serious events
Hemorrhage of digestive tract
Zhu et al[17]	22	1	25	3	0.42 (0.04, 4.30)
Cerebral hernia
Tian et al[18]	23	2	23	6	0.35 (0.06, 1.90)
Bradycardia
Fu et al[16]	11	1	12	0	N/A
Atrial flutter
Tian et al[18]	23	2	23	0	N/A
Thrombocytopenia
Tian et al[18]	23	2	23	0	N/A